Back

Correlation of electrocardiographic reverse remodelling with treatment response to mavacamten in hypertrophic obstructive cardiomyopathy

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors: real-world data Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Mustapha Menhem

University Hospital Erlangen, Erlangen (Germany)

4 More presentations in this session

Presentation thumbnail
Real-world data on the use of mavacamten in obstructive hypertrophic cardiomyopathy: one-year data from the multicentre MARVEL.HU study involving 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Predictors of functional status and quality-of-life improvement with mavacamten in obstructive hypertrophic cardiomyopathy: one-year results from a real-world nationwide cohort
Doctor G. Bonacchi (Florence, IT)
Abstract Slides Video
Presentation thumbnail
From evidence to practice: Mavacamten in obstructive Hypertrophic Cardiomyopathy - data from the multicenter TORCH-Plus-DZHK21 registry
Doctor J. Koelemen (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Real-world experience and structural remodeling with cardiac myosin inhibitors in hypertrophic obstructive cardiomyopathy: Insights from a Heart Failure Network Registry
Doctor D. Jurczyk (Luebeck, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibitors: real-world data

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten
29 August 2025
thumbnail
Congress Presentation
Decrease of ECG hypertrophy indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy
19 May 2025
thumbnail
Congress Presentation
Evaluation of the hypothetical risk of sudden cardiac death in obstructive HCM patients treated with mavacamten using the HCM Risk-SCD score
29 August 2026
thumbnail
Congress Presentation
One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources